135 related articles for article (PubMed ID: 21789026)
1. Rhabdomyolysis from erlotinib: a case report.
Moscetti L; Nelli F; Ruggeri EM
Tumori; 2011; 97(3):415-6. PubMed ID: 21789026
[No Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
[No Abstract] [Full Text] [Related]
3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
4. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
5. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
6. Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.
Nagai H; Tanaka S; Niimi M; Seo N; Sasaki T; Date H; Mishima M; Yasuda H; Yanagihara K
Int J Clin Oncol; 2011 Oct; 16(5):560-7. PubMed ID: 21625893
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Bugés C; Carcereny E; Moran T; Cardona AF; Reguart N; Capdevila L; Cros S; Rosell R
Clin Lung Cancer; 2015 Mar; 16(2):e1-3. PubMed ID: 25550194
[No Abstract] [Full Text] [Related]
8. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
10. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Burotto M; Ali SA; O'Sullivan Coyne G
Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
Laterza MM; Chiurazzi B; Brangi M; Riccardi F; Cartenì G
Tumori; 2013; 99(1):3e-5e. PubMed ID: 23549019
[TBL] [Abstract][Full Text] [Related]
12. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
13. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Macerelli M; Mazzer M; Foltran L; Cardellino GG; Aprile G
Tumori; 2015 Jul; 101(4):e122-7. PubMed ID: 25953445
[TBL] [Abstract][Full Text] [Related]
14. Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report.
Pinquié F; de Chabot G; Urban T; Hureaux J
Oncology; 2016; 90(3):176-7. PubMed ID: 26886479
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Perez-Soler R
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S20-3. PubMed ID: 15638953
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
18. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Guo R; Chen X; Wang T; Zhang Z; Sun J; Shu Y
BMC Cancer; 2011 Mar; 11():90. PubMed ID: 21366910
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyolysis Caused by Gefitinib Overdose.
Obayashi S; Tomomatsu K; Urata M; Tanaka J; Niimi K; Hayama N; Oguma T; Asano K; Ito Y
Intern Med; 2022 May; 61(10):1577-1580. PubMed ID: 34707044
[TBL] [Abstract][Full Text] [Related]
20. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Bunn PA
J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
[No Abstract] [Full Text] [Related]
[Next] [New Search]
